ArticleIndian dermatology online journal2026
Therapeutic Efficacy and Safety of Oral Cyclosporine and that of Oral Prednisolone in the Management of Refractory Oral Lichen Planus: A Comparative Study.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral lichen planus (OLP) is a chronic autoimmune disorder of the oral mucosa that often requires long-term treatment due to its relapsing nature. While corticosteroids remain the first-line therapy, refractory cases necessitate alternative treatments. Cyclosporine, an immunosuppressant, has shown potential efficacy in OLP management, but lacks comparative studies with oral prednisolone, a commonly used systemic corticosteroid. AIM AND
objectiveTo compare the efficacy and safety of oral cyclosporine versus oral prednisolone in managing refractory oral lichen planus. PATIENTS AND
methodsA prospective, randomized, controlled trial was conducted at a tertiary care hospital in eastern India, enrolling patients with refractory OLP. Participants were randomly assigned to receive either oral cyclosporine or oral prednisolone. Efficacy was evaluated using improvement in the oral disease severity score (ODSS), dermatology life quality index (DLQI), and visual analogue scale (VAS), while safety was assessed by monitoring adverse events, laboratory markers, and patient tolerance.
resultsBoth treatment groups showed significant improvement in ODSS and DLQI scores ( P < 0.05). The cyclosporine group had a 92.7% reduction in ODSS compared to 88.8% in prednisolone group( P =0.03), while DLQI improved by 84.8% versus 78.08% ( P =0.04). Prednisolone was associated with higher rates of hyperglycemia and hypertension, whereas cyclosporine posed a risk of nephrotoxicity and relapses. LIMITATIONS: A short follow-up period and a small sample size were limitations.
conclusionTo conclude, cyclosporine appears to be an effective and safe alternative to prednisolone, warranting further studies with a larger sample size and extended follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.